NEOpredict-OMD
Immunotherapy-based, multimodal treatment strategies in oligometastatic non-small cell lung cancer: A randomized, low-interventional clinical trial of local ablative therapy guided by metabolic treatment response
II
interventionell
National
PET/CT-guided, multimodal treatment strategy for OMD NSCLC as compared to a strategy that involves LAT of all known lesions
Status: In Vorbereitung
Zeitraum
2027
2030
Zentren
11
Keine Zentren gesucht
Patienten
155
07.10.2026
Klinische Settings
IVA, IVB
1st line
palliativ
Identifier
AIO-TRK-0426/ass
NEOpredict-OMD
2026-528364-25-00
Kontakt
Leitung
Prof. Dr. med. Marcel Wiesweg
Dr. med. Franziska Glanemann
Ansprechpartner*in
Prof. Dr. med. Marcel Wiesweg
E-Mail marcel.wiesweg@uk-essen.de